“Anti-Integrin Therapy in Treatment of DME”

Agent shows novel mechanism of action, binding in the retina to stop angiogenesis.

Integrins have recently emerged as a treatment target in vitreoretinal diseases. Like VEGF, they are a part of the angiogenic cascade. Integrins are involved in cell-surface interactions that allow new endothelial cells to grow in the extracellular space. Without the expression of integrins, neovascularization would not occur. Integrin receptors cross-activate receptors for VEGF and for platelet-derived growth factor, demonstrating that these factors are closely interrelated in the angiogenesis pathway.

To read the article, please visit Retina Today“Anti-Integrin Therapy in Treatment of DME”